Person: Herrero Vanrell, María Del Rocío
Loading...
First Name
María Del Rocío
Last Name
Herrero Vanrell
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Farmacia Galénica y Tecnología Alimentaria
Area
Farmacia y Tecnología Farmaceútica
Identifiers
15 results
Search Results
Now showing 1 - 10 of 15
Item Smart biodegradable hydrogels: Drug-delivery platforms for treatment of chronic ophthalmic diseases affecting the back of the eye(International Journal of Pharmaceutics, 2024) Aragón Navas, Alba; López-Cano, José Javier; Johnson, Melissa; A, Sigen; Vicario De La Torre, Marta; Andrés Guerrero, Vanesa; Tai, Hongyun; Wang, Wenxin; Bravo Osuna, Irene; Herrero Vanrell, María Del RocíoThis paper aims to develop smart hydrogels based on functionalized hyaluronic acid (HA) and PLGA-PEG-PLGA (PLGA,poly-(DL-lactic-co-glycolic acid); PEG,polyethylene glycol) for use as intraocular drug-delivery platforms. Anti-inflammatory agent dexamethasone-phosphate (0.2 %w/v) was the drug selected to load on the hydrogels. Initially, different ratios of HA-aldehyde (HA-CHO) and thiolated-HA (HA-SH) were assayed, selecting as optimal concentrations 2 and 3 % (w/v), respectively. Optimized HA hydrogel formulations presented fast degradation (8 days) and drug release (91.46 ± 3.80 % in 24 h), thus being suitable for short-term intravitreal treatments. Different technology-based strategies were adopted to accelerate PLGA-PEG-PLGA water solubility, e.g. substituting PEG1500 in synthesis for higher molecular weight PEG3000 or adding cryopreserving substances to the buffer dissolution. PEG1500 was chosen to continue optimization and the final PLGA-PEG-PLGA hydrogels (PPP1500) were dissolved in trehalose or mannitol carbonate buffer. These presented more sustained release (71.77 ± 1.59 % and 73.41 ± 0.83 % in 24 h, respectively) and slower degradation (>14 days). In vitro cytotoxicity studies in the retinal-pigmented epithelial cell line (RPE-1) demonstrated good tolerance (viability values > 90 %). PLGA-PEG-PLGA hydrogels are proposed as suitable candidates for long-term intravitreal treatments. Preliminary wound healing studies with PLGA-PEG-PLGA hydrogels suggested faster proliferation at 8 h than controls.Item Nano and microtechnologies for ophthalmic administration. An overview(Journal of Drug Delivery Science and Technology, 2013) Herrero Vanrell, María Del Rocío; Vicario De La Torre, Marta; Andrés-Guerrero, Vanessa; Barbosa-Alfaro, Deyanira; Molina Martínez, Irene Teresa; Bravo Osuna, IreneOcular drug delivery is one of the most challenging fields of pharmaceutical research. They are generally employed to overcome the static (different layers of cornea, sclera, and retina including blood aqueous and blood-retinal barriers) and dynamic barriers (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution) of the eye. Ophthalmic formulations must be sterile, and the biomaterials used in the preparation of pharmaceutical systems completely compatible and extremely well tolerated by ocular tissues. The location of the target tissue in the eye will determine the route of administration. Ophthalmic administration systems are intended for topical, intraocular and periocular administration. In this review we describe the main pharmaceutical nano- and microsystems currently under study to administrate drugs in the eye, covering microparticles, nanoparticles, liposomes, microemulsions, niosomes and dendrimers. We have performed the corresponding revision of the published scientific literature always emphasizing the technological aspects. The review discusses also the biomaterials used in the preparation of the nano and microsystems of ophthalmic drug delivery, fabrication techniques, therapeutic significances, and future possibilities in the field.Item Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents(Drug Delivery and Translational Research, 2024) Brugnera, Marco; Vicario De La Torre, Marta; González-Cela Casamayor, Miriam Ana; López Cano, José Javier; Bravo Osuna, Irene; Huete Toral, Fernando; González Rubio, María Luisa; Carracedo Rodríguez, Juan Gonzalo; Molina Martínez, Irene Teresa; Andrés Guerrero, Vanesa; Herrero Vanrell, María Del RocíoThe first line of glaucoma treatment focuses on reducing intraocular pressure (IOP) through the prescription of topical prostaglandin analogues, such as latanoprost (LAT). Topical ophthalmic medicines have low bioavailability due to their rapid elimination from the ocular surface. Nanotechnology offers innovative ways of enhancing the ocular bioavailability of antiglaucoma agents while reducing administration frequency. This study aims to combine LAT-loaded synthetic phosphatidylcholine liposomes with hyaluronic acid (0.2% w/v) and the osmoprotectants betaine (0.40% w/v) and leucine (0.90% w/v) (LAT-HA-LIP) to extend the hypotensive effect of LAT while protecting the ocular surface. LAT-HA-LIP was prepared as a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol and α-tocopherol acetate. LAT-HA-LIP exhibited high drug-loading capacity (104.52 ± 4.10%), unimodal vesicle sizes (195.14 ± 14.34 nm) and a zeta potential of -13.96 ± 0.78 mV. LAT-HA-LIP was isotonic (284.00 ± 1.41 mOsm L-1), had neutral pH (7.63 ± 0.01) and had suitable surface tension (44.07 ± 2.70 mN m-1) and viscosity (2.69 ± 0.15 mPa s-1) for topical ophthalmic administration. LAT-HA-LIP exhibited optimal in vitro tolerance in human corneal and conjunctival epithelial cells. No signs of ocular alteration or discomfort were observed when LAT-HA-LIP was instilled in albino male New Zealand rabbits. Hypotensive studies revealed that, after a single eye drop, the effect of LAT-HA-LIP lasted 24 h longer than that of a marketed formulation and that relative ocular bioavailability was almost three times higher (p < 0.001). These findings indicate the potential ocular protection and hypotensive effect LAT-HA-LIP offers in glaucoma treatment.- Project number: 372
Item Resiliencia y adaptabilidad en Farmacia: Aprovechamiento de la experiencia de enseñanza-aprendizaje en tiempos de pandemia por CoVid19 aplicando B-Learning y learning analytics(2022) Notario Pérez, Fernando; Ruiz Caro, Roberto; Veiga Ochoa, María Dolores; Molina Martínez, Irene Teresa; Herrero Vanrell, María Del Rocío; Bravo Osuna, Irene; Vicario De La Torre, Marta; Martin Erdocia, Izaskun; Cazorla Luna, Raúl; García Herranz, David; López Cano, José Javier; Martín Illana, Araceli; Gil Alegre, María Esther; Andrés Guerrero, Vanesa; Aragón Navas, Alba Item Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects(International Journal of Molecular Sciences, 2019) Suárez Barrio, Carlota; Etxebarria, Jaime; Hernáez Moya, Raquel; del Val Alonso, Marina; Rodriguez Astigarraga, Maddalen; Urkaregi, Arantza; Freire, Vanesa; Morales, María Celia; Durán, Juan; Vicario De La Torre, Marta; Molina Martínez, Irene Teresa; Herrero Vanrell, María Del Rocío; Andollo, NoeliaThe aim of this study is to assess if an adhesive biopolymer, sodium hyaluronate (NaHA), has synergistic effects with s-PRGF (a serum derived from plasma rich in growth factors and a blood derivative that has already shown efficacy in corneal epithelial wound healing), to reduce time of healing or posology. In vitro proliferation and migration studies, both in human corneal epithelial (HCE) cells and in rabbit primary corneal epithelial (RPCE) cultures, were carried out. In addition, we performed studies of corneal wound healing in vivo in rabbits treated with s-PRGF, NaHA, or the combination of both. We performed immunohistochemistry techniques (CK3, CK15, Ki67, ß4 integrin, ZO-1, α-SMA) in rabbit corneas 7 and 30 days after a surgically induced epithelial defect. In vitro results show that the combination of NaHA and s-PRGF offers the worst proliferation rates in both HCE and RPCE cells. Addition of NaHA to s-PRGF diminishes the re-epithelializing capability of s-PRGF. In vivo, all treatments, given twice a day, showed equivalent efficacy in corneal epithelial healing. We conclude that the combined use of s-PRGF and HaNA as an adhesive biopolymer does not improve the efficacy of s-PRGF alone in the wound healing of corneal epithelial defects.Item The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies(Progress in Retinal and Eye Research, 2014) Herrero Vanrell, María Del Rocío; Bravo Osuna, Irene; Andrés-Guerrero, Vanessa; Vicario De La Torre, Marta; Molina Martínez, Irene TeresaPathologies affecting the posterior segment are one of the major causes of blindness in developed countries and are becoming more prevalent due to the increase in society longevity. Sucessful therapy of diseases affecting the back of the eye requires effective concentrations of the active substance mantained during a long period of time in the intraocular target site. Treatment of vitreoretinal diseases often include repeated intravitreous injections that are associated with adverse effects. Local administration of biodegradable microspheres offers an excellent alternative to multiple administrations, as they are able to deliver the therapeutic molecule in a controlled fashion. Furthermore, injection of microparticles is performed without the need for surgical procedures. As most of the retinal diseases are multifactorial, microspheres result especially promising because they can be loaded with more than one active substance and complemented with the inclusion of additives with pharmacological properties. Personalized therapy can be easily achieved by changing the amount of administered microspheres. Contrary to non-biodegradable devices, biodegradable PLA and PLGA microspheres disappear from the site of administration after delivering the drug. Furthermore, microspheres prepared from these mentioned biomaterials are well tolerated after periocular and intravitreal injections in animals and humans. After injection, PLA and PLGA microspheres suffer aggregation behaving like an implant. Biodegradable microspheres are potential tools in regenerative medicine for retinal repair. According to the reported results, presumably a variety of microparticulate formulations for different ophthalmic therapeutic uses will be available in the clinical practice in the near future.Item Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film(Polymers, 2018) Vicario De La Torre, Marta; Caballo González, María; Vico Ruiz, Eva; Morales Fernández, Laura; Arriola Villalobos, Pedro; Heras Polo, Beatriz De Las; Benítez Del Castillo Sánchez, José Manuel; Guzmán Navarro, Manuel; Millar, Thomas; Herrero Vanrell, María Del Rocío; Molina Martínez, Irene TeresaDry eye is commonly treated with artificial tears; however, developing artificial tears similar to natural tears is difficult due to the complex nature of tears. We characterized and evaluated a novel artificial tear formulation with components similar to the lipid and aqueous constituents of natural tears. Nano-liposomes, composed in part of phosphatidylcholine, were dispersed in an aqueous solution of bioadhesive sodium hyaluronate. Liposome size, zeta potential, and physicochemical properties of the fresh and stored (4°C) liposomal formulation were analyzed. In vitro tolerance was tested using human corneal and conjunctival cell lines by exposures of 15 min to 4 h. The tolerance of the liposomal formulation was evaluated in animals (rabbits). The average liposome size was 186.3 +/- 7.0 nm, and the zeta potential was negative. The osmolarity of the formulation was 198.6 +/- 1.7 mOsm, with a surface tension of 36.5 +/- 0.4 mN/m and viscosity of 3.05 +/- 0.02 mPa·s. Viability values in the human corneal and conjunctival cell lines were always >80%, even after liposomal formulation storage for 8 weeks. Discomfort and clinical signs after instillation in rabbit eyes were absent. The new formulation, based on phosphatidylcholine-liposomes dispersed in sodium hyaluronate has suitable components and characteristics, including high in vitro cell viability and good in vivo tolerance, to serve as a tear substitute.Item Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In vitro and ex vivo functionality studies in corneal epithelial cells(Experimental Eye Research, 2017) Soriano Romaní, Laura; Vicario De La Torre, Marta; López García, Antonio; Crespo Moral, Mario; Herrero Vanrell, María Del Rocío; Molina Martínez, Irene Teresa; Diebold Luque, YolandaIn ocular surface inflammatory diseases, such as dry eye disease, long-term symptom relief requires targeting the inflammation itself rather than treating only the surface-associated dryness with artificial tears. Therefore, we included an anti-inflammatory agent in an unpreserved liposome-based (LP) formulation used as artificial tears. Our aim was to characterize and study its in vitro and ex vivo cell uptake and functionality. Human corneal epithelial (HCE) cells were used to study MPA-LP37 induced effects after 60 min of exposure, using blank LP and non-LP MPA formulations as controls. A fluorescent labeled LP formulation was used to determine uptake by HCE cells and localization in ex vivo porcine corneas. The LP formulation complied with the required physicochemical properties and had no cytotoxicity on HCE cells after 60 min of exposure. HCE cells showed LP-associated fluorescence at 24, 48, and 72 h after 60 min of exposure, and the LP-associated fluorescence was uniformly distributed throughout the porcine corneal epithelium immediately after 5 min of exposure. MPA44 LP increased protein expression and nuclear translocation of progesterone receptor in comparison with controls as determined by Western blotting and immunofluorescence. Moreover, MPA-LP significantly reduced the cell proliferation rate and IL-6 and IL-8 production 48 h after the exposure period, as determined by the alamarBlue assay and ELISA, respectively. None of these effects were evident in blank LP-exposed cells and non-LP MPA formulation reduced only IL-6 production. Our results suggest that the LP50 based formulation, used to replenish the lipids of the tear film, can be loaded with anti-inflammatory agents that can be delivered into the cells and activate specific drug receptors. These agents can reduce inflammatory cytokine production and may be effective in the treatment of inflammatory processes associated with ocular surface diseases.Item Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents(Drug Delivery and Translational Research, 2024) Brugnera, Marco; Vicario De La Torre, Marta; González-Cela Casamayor, Miriam Ana; López Cano, José Javier; Bravo Osuna, Irene; Huete Toral, Fernando; González Rubio, María Luisa; Carracedo Rodríguez, Juan Gonzalo; Molina Martínez, Irene Teresa; Andrés Guerrero, Vanesa; Herrero Vanrell, María Del RocíoThe first line of glaucoma treatment focuses on reducing intraocular pressure (IOP) through the prescription of topical prostaglandin analogues, such as latanoprost (LAT). Topical ophthalmic medicines have low bioavailability due to their rapid elimination from the ocular surface. Nanotechnology offers innovative ways of enhancing the ocular bioavailability of antiglaucoma agents while reducing administration frequency. This study aims to combine LAT-loaded synthetic phosphatidylcholine liposomes with hyaluronic acid (0.2% w/v) and the osmoprotectants betaine (0.40% w/v) and leucine (0.90% w/v) (LAT-HA-LIP) to extend the hypotensive effect of LAT while protecting the ocular surface. LAT-HA-LIP was prepared as a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol and α-tocopherol acetate. LAT-HA-LIP exhibited high drug-loading capacity (104.52 ± 4.10%), unimodal vesicle sizes (195.14 ± 14.34 nm) and a zeta potential of -13.96 ± 0.78 mV. LAT-HA-LIP was isotonic (284.00 ± 1.41 mOsm L−1), had neutral pH (7.63 ± 0.01) and had suitable surface tension (44.07 ± 2.70 mN m−1) and viscosity (2.69 ± 0.15 mPa s−1) for topical ophthalmic administration. LAT-HA-LIP exhibited optimal in vitro tolerance in human corneal and conjunctival epithelial cells. No signs of ocular alteration or discomfort were observed when LAT-HA-LIP was instilled in albino male New Zealand rabbits. Hypotensive studies revealed that, after a single eye drop, the effect of LAT-HA-LIP lasted 24 h longer than that of a marketed formulation and that relative ocular bioavailability was almost three times higher (p < 0.001). These findings indicate the potential ocular protection and hypotensive effect LAT-HA-LIP offers in glaucoma treatment.Item Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea(Acta Ophthalmologica, 2021) Díaz Valle, David; Burgos Blasco, Bárbara; Rego Lorca, Daniela; Puebla Garcia, Virginia; Pérez García, Pilar; Benítez Del Castillo Sánchez, José Manuel; Herrero Vanrell, María Del Rocío; Vicario De La Torre, Marta; Gegúndez Fernández, José AntonioPurpose: To investigate the effect of topical insulin on epithelization in persistent epithelial defects (PED) refractory to usual treatment compared to autologous serum. Design: Retrospective, consecutive case–control series. Methods: The charts of 61 consecutive patients with PED treated with topical insulin (case group) and 23 treated with autologous serum (control group) were reviewed. Primary efficacy end points were the percentage of patients in which epithelization was achieved, as well as the rate and time until epithelization. Secondary efficacy point was need for amniotic membrane transplantation (AMT) or other surgeries. Results: Mean time between PED diagnosis and start of topical insulin was 22.7 � 18.5 days (range 13–115) and the mean area was 14.8 � 16.2 mm2 (range 1.1–70.6). In the control group, mean time was 27.9 � 16.8 days, mean epithelial defect area being 18.6 � 15.0 mm2 (range 1.7–52.9). No differences in baseline characteristics were found between groups (p > 0.05). Epithelization was achieved in 51 patients (84%) on insulin and 11 patients (48%) on autologous serum (p = 0.002). In those patients, mean time until reepithelization was 32.6 � 28.3 days (range 4–124) in the insulin group and 82.6 � 82.4 days (range 13–231) in the autologous serum group (p = 0.011). The need for AMT was significantly lower in the insulin group (p = 0.005). PED recurrence was higher in patients treated on autologous serum (43%) compared with insulin (11%) (p = 0.002). Conclusions: Topical insulin is an effective treatment and safely promotes healing of PED. In our series, topical insulin presented better epithelization outcomes than autologous serum and could thus be considered as a first-line treatment.